| Name | Title | Contact Details |
|---|
Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elabscience is a biotech corporation that specializes in laboratory reagents for life science research, including ELISA kits, FCM antibodies, biochemical kits, antibodies, and proteins.
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently as possible. Chugai`s specific focus is placed on bringing innovative therapies to market for conditions where treatment options may be limited and patient needs may be unmet. Chugai works in strategic alliance with Roche to pursue cutting-edge biopharmaceutical, antibody, and molecular-targeted research technologies-areas that constitute Chugai`s greatest strengths-as well as chemical synthesis technology. Chugai has achieved success with its original products and will continue to seek to provide exceptional value to patients. As a most important member of the Roche group, Chugai aims to become a top pharmaceutical company by providing a continuous flow of innovative new medicines internationally. CPUSA believes in success through collaboration, and our culture encourages innovation through sharing ideas. If being on the cutting edge of translational clinical research and development appeals to you, consider a career with CPUSA.
We are passionate about improving people`s daily lives by offering clinically proven solutions to common skin and eye care problems through digital channels, traditional domestic retailers, and international distributors. We are in the process of growing from a small single-product company into a profitable mid-sized multi-product company. Our leading product, Avenova®, is the only lid & lash solution that brings eyes back to life by setting the highest standards of purity and efficacy. We pioneered the use of hypochlorous acid in the eyecare space and intend on making Avenova a household name. Our motto is, “If you have eyes, you need Avenova!” We also recently acquired DERMAdoctor, LLC, a skincare company offering more than 30 dermatologist-developed skincare products. We plan to launch nine new products this year with the founder of DERMAdoctor doing well known media placements such as QVC.
"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. "